Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BIO 2021 Notebook: Biogen CEO On Corporate Responsibility

Jun 17 2021

• By Scrip Team and Pink Sheet Team

BIO 2021 Notebook - Day 4

Related Content

CDER Planning Guidances On Single-Trial Approvals, Real-World Evidence

Jan 26 2021

New Opioids May Need Comparative Effectiveness Data For Approval

Jun 21 2019

Polarizing Fight Looms As US FDA Seeks Comment On Abuse-Deterrent Stimulants

Sep 24 2019

China's CARsgen Raises $400m In Third-Largest Biotech IPO This Year

Jun 17 2021

BIO 2021 Notebook: Looking Past The Pandemic

Jun 14 2021

Biogen/Eisai Win On Aduhelm Approval Bet And Wager Next On Price

Jun 07 2021

ADHD Advisory Committee Wants FDA-Defined Standards Before Clearing Abuse-Deterrent Stimulant Label

Oct 12 2020

US FDA Has Soured On Abuse Deterrent Labeling Even Outside Of Opioids, Stimulant Docs Suggest

Oct 07 2020

Related Companies

Biogen, Inc.

Allogene Therapeutics Inc.

FUJIFILM Diosynth Biotechnologies

Arbor Pharmaceuticals, LLC

Gilead Sciences, Inc.

CARsgen Therapeutics Holdings Limited

Additional Topics

Clinical Trials Companies Diversity & Inclusion Drug Approval Standards FDA Intellectual Property Manufacturing Regulation Strategy

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window